Renaparin® in Kidney Transplantation

Inclusion Criteria: Organs: * Kidney must come from a deceased donor above 18 years of age * The regular protocols for organ donation according to Swedish law can be followed Patients: * Male and female patients 18 - 75 years of age. * Ability to provide written informed consent. * Mentally stable and able to comply with the procedures of the study protocol * Patient has been listed for kidney transplantation from a deceased donor at the clinical sites included in this study. * Negative crossmatch test prior to transplantation and no existence of donor-specific antibodies * Receiving first or second renal transplantation Exclusion Criteria: Organs: * Organs from donors deceased due to cardiac death. * Organs which have not been adequately perfused during HMP, as judged by the transplantation surgeon on call. Patients: * Use of an investigational drug or other investigational treatment, that could interfere with the outcome of the present trial, in the 30 days' period before Study Day 1 * Increased risk of thrombosis (ex. homozygous APC-resistance) or bleeding (INR\>1.5) * Anticoagulant treatment with Warfarin for indication unrelated to the kidney transplantation * History of heparin-induced thrombocytopenia (HIT) * History of or positive for HIV, HBV, or HCV * History of oncological malignancy within the last five years, except excised squamous or basal cell carcinoma of the skin * Scheduled to undergo multi-organ transplantation or dual kidney transplantation * Current drug and/or alcohol abuse * Known fish allergy * History or presence of a medical condition or disease or psychiatric condition that in the investigator's assessment would place the patient at an unacceptable risk for study participation * Lactating or pregnant women or women who intend to become pregnant * Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during study treatment. Acceptable birth control methods are those with a failure rate of less than 1% per year when used consistently and correctly. Such methods include (in "Recommendations related to contraception and pregnancy testing in clinical trials", supplied from www.hma.eu/): 1. Combined (estrogen and progestogen containing hormonal contraception associated with inhibition of ovulation * oral * intravaginal * transdermal 2. progestogen-only hormonal contraception associated with inhibition of ovulation * oral * injectable * implantable 3. intrauterine device 4. intrauterine hormone-releasing system 5. bilateral tubal occlusion 6. vasectomized partner * Patients who the investigator considers not eligible to give informed consent * Presence of ECG-based evidence of acute myocardial infarction, unstable angina, decompensated heart failure, third degree of heart block or cardiac arrhythmia associated with hemodynamic stability * Patients with any condition or any circumstance that in the opinion of the investigator would make it unsafe to undergo a kidney transplantation